Cel-Sci Corporation

16.35-0.3300-1.98%Vol 692.33K1Y Perf 468.55%
Feb 25th, 2020 16:00
BID16.29 ASK16.36
Open16.62 Previous Close16.68
Pre-Market16.80 After-Market16.15
 0.12 0.72%  -0.20 -1.22%
Target Price
18.50 
Analyst Rating
Strong Buy 1.00
Potential %
13.15 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/-/33 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/-25/-14 
Growth Ranking
★+ —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/-21/-5 
Income Ranking
 —    -
Market Cap595.58M 
Earnings Rating
Buy
Price Range Ratio 52W %
90.60 
Earnings Date
13th Feb 2020

Today's Price Range

15.6816.92

52W Range

2.3717.80

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
1.62%
1 Month
17.12%
3 Months
118.29%
6 Months
112.34%
1 Year
468.55%
3 Years
626.67%
5 Years
-31.88%
10 Years
-90.38%

TickerPriceChg.Chg.%
CVM16.35-0.3300-1.98
AAPL288.08-10.1000-3.39
GOOG1 388.45-33.1400-2.33
MSFT168.07-2.8200-1.65
XOM54.21-2.1500-3.81
WFC45.11-1.2800-2.76
JNJ144.65-1.2600-0.86
FB196.77-3.9500-1.97
GE11.32-0.5400-4.55
JPM126.26-5.9000-4.46
Earnings HistoryEstimateReportedSurprise %
Q01 2020-0.15-0.16-6.67
Q04 2019-0.09-0.20-122.22
Q03 2019-0.10-0.37-270.00
Q02 2019-0.12-0.19-58.33
Q01 2019--0.17-
Q04 2018--0.70-
Q03 2018--0.36-
Q02 2018--0.31-
Earnings Per EndEstimateRevision %Trend
3/2020 QR-0.1646.67Positive
6/2020 QR-0.13-134.21Negative
9/2020 FY-0.56--
9/2021 FY-0.41--
Next Report Date-
Estimated EPS Next Report-0.15
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume692.33K
Shares Outstanding36.43M
Trades Count3.84K
Dollar Volume5.79M
Avg. Volume1.01M
Avg. Weekly Volume1.04M
Avg. Monthly Volume822.61K
Avg. Quarterly Volume835.69K
Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
1 (100.00 %)
1 (100.00 %)
0
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0
Hold
0 (0.00 %)
0 (0.00 %)
0
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0
Strong Sell
0 (0.00 %)
0 (0.00 %)
0
Summary RatingStrong Buy
1.00
Strong Buy
1.00
-

Cel-Sci Corporation

CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

CEO: Geert R. Kersten

Teplephone: +1 703 506-9460

Address: 8229 Boone Boulevard, Vienna 22182, VA, USA

Number of employees: 0

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

75%25%

Bearish Bullish

61%39%

Bearish Bullish

60%40%

News

Stocktwits